SLC41A2: A Potential Drug Target and Biomarker for Various Diseases

Target Name: SLC41A2

NCBI ID: G84102

SLC41A2

SLC41A2: A Potential Drug Target and Biomarker for Various Diseases

SLC41A2, also known as SLC41A2 gene, is a member of the Solute carrier family 41 (SLC41) and is located on chromosome 12. It is a gene that encodes a protein known as A2 isoform, which is a key protein in the isoform A family of transmembrane proteins. The isoform A family is a family that is widely found in various cells and tissues, and their functions include cell signaling, protein transport, and intracellular signaling.

SLC41A2 is a splice variants gene and there are four isoforms of it, isoform A, isoform B, isoform C and isoform D. These isoforms are different in their amino acid sequences, but all of them share a common region of 120 amino acids. The common region is responsible for the transmembrane portion of the protein, which is involved in its function.

SLC41A2 is expressed in various tissues and cells of the body, including the brain, heart, skeletal muscles, and tissues of the digestive system. It is also highly expressed in the placenta, which supports the development and growth of new fetuses. SLC41A2 is also expressed in various cell types of the immune system, such as dendritic cells, macrophages, and B cells.

SLC41A2 has been identified as a potential drug target and a biomarker for various diseases, including cancer, cardiovascular disease, and neurological disorders. One of the reasons for its potential as a drug target is its involvement in various signaling pathways, including cell signaling, angiogenesis , and inflammation.

SLC41A2 has been shown to play a role in cell signaling, specifically in the regulation of cell proliferation and differentiation. It has been shown to promote the growth and survival of various cancer cell lines, and it has also been shown to inhibit the migration and invasion of cancer cells. These findings suggest that SLC41A2 may be a useful target for cancer therapies.

SLC41A2 has also been shown to be involved in the regulation of angiogenesis, which is the process by which new blood vessels form in the body. It has been shown to promote the formation of new blood vessels in the brain and has been shown to protect existing blood vessels from damage. These findings suggest that SLC41A2 may be a useful target for angiogenesis-related therapies.

SLC41A2 has also been shown to be involved in the regulation of inflammation. It has been shown to promote the production of pro-inflammatory cytokines and has been shown to contribute to the development of chronic inflammatory diseases. These findings suggest that SLC41A2 may be a useful target for anti-inflammatory therapies.

In addition to its potential as a drug target, SLC41A2 has also been shown to be a potential biomarker for various diseases. For example, it has been shown to be elevated in the blood of patients with various neurological disorders, including Alzheimer's disease, Parkinson's disease , and multiple sclerosis. These findings suggest that SLC41A2 may be a useful biomarker for these disorders.

Overall, SLC41A2 is a gene that has the potential to be a drug target and a biomarker for various diseases. Further research is needed to fully understand its functions and to develop effective therapies based on its potential.

Protein Name: Solute Carrier Family 41 Member 2

Functions: Acts as a plasma-membrane magnesium transporter

The "SLC41A2 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about SLC41A2 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets